[
  {
    "ts": null,
    "headline": "Zimmer Biomet Holdings Inc. stock outperforms competitors despite losses on the day",
    "summary": "Zimmer Biomet Holdings Inc. stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=21ac6da65fec58ca17437ff2842dc63f6be0cc3d31cac4c5ee6046a51f1ef2a5",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734628320,
      "headline": "Zimmer Biomet Holdings Inc. stock outperforms competitors despite losses on the day",
      "id": 132158743,
      "image": "",
      "related": "ZBH",
      "source": "MarketWatch",
      "summary": "Zimmer Biomet Holdings Inc. stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=21ac6da65fec58ca17437ff2842dc63f6be0cc3d31cac4c5ee6046a51f1ef2a5"
    }
  },
  {
    "ts": null,
    "headline": "Zimmer Biomet price target raised to $118 from $117 at Truist",
    "summary": "Truist raised the firm’s price target on Zimmer Biomet (ZBH) to $118 from $117 and keeps a Hold rating on the shares as part of a broader research note previewing 2025 in Medical Technology. The firm sees the sector as “one of the better/safer houses” in healthcare given its lower “front-line” exposure to healthcare policy rhetoric that is tied to the administration change as well as its position as an “innovation segment” with sustainable above-average revenue and EPS growth, strong balance she",
    "url": "https://finnhub.io/api/news?id=ff776212bdba6ee299f5fa5c0e0d168823853b9dd8a30e9004fb02c240568f29",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734611779,
      "headline": "Zimmer Biomet price target raised to $118 from $117 at Truist",
      "id": 132057641,
      "image": "https://media.zenfs.com/en/tipranks_452/4228d494699edc69b7f529ca87ad9ce2",
      "related": "ZBH",
      "source": "Yahoo",
      "summary": "Truist raised the firm’s price target on Zimmer Biomet (ZBH) to $118 from $117 and keeps a Hold rating on the shares as part of a broader research note previewing 2025 in Medical Technology. The firm sees the sector as “one of the better/safer houses” in healthcare given its lower “front-line” exposure to healthcare policy rhetoric that is tied to the administration change as well as its position as an “innovation segment” with sustainable above-average revenue and EPS growth, strong balance she",
      "url": "https://finnhub.io/api/news?id=ff776212bdba6ee299f5fa5c0e0d168823853b9dd8a30e9004fb02c240568f29"
    }
  }
]